GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced two major initiatives to make ...
The Daily Overview on MSN
New deal could cut an obesity drug to $149 a month
President Trump recently announced a significant development in the realm of healthcare, focusing on the affordability and ...
New cash-paying patients can now access Wegovy/Ozempic for $199 a month. Here's what that means for Novo Nordisk stock.
Novo Nordisk (NVO) is deeply undervalued after a 43% YTD decline, despite strong fundamentals and global obesity market ...
The Daily Overview on MSN
Medicare will cover obesity drugs under Trump deal, from $50
President Trump has successfully negotiated a groundbreaking deal to include obesity drugs under Medicare coverage, marking a ...
LillyDirect’s Jennifer Mazur on the platform’s new partnership with Walmart, future of DTC platforms
Mazur, GM of LillyDirect, breaks down the platform’s new partnership with Walmart and its implications for the pharma ...
Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain ...
Under its terms, those products will be sold by their developers through a planned national online drug platform called ...
A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and ...
3don MSN
Prices cut for popular obesity treatment, but doctors still see cost challenges for patients
Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without ...
The GoodRx for Weight Loss telemedicine subscription is available for an introductory rate of $39 per month through January ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback